🇺🇸 FDA
Patent

US 11795234

Methods of producing muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

granted A61KA61K2039/505A61K47/6807

Quick answer

US patent 11795234 (Methods of producing muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide) held by Dyne Therapeutics, Inc. expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Dyne Therapeutics, Inc.
Grant date
Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2039/505, A61K47/6807, A61K47/6849, A61K47/6889